🔍

Jfl Life Sciences Limited (JFLLIFE)

📊 NSE: JFLLIFE 🏢 Pharmaceuticals - Indian - Formulations 📢 Latest filing: 02 Oct 2026 📝 Analysis written: 14 Dec 2025

Latest quarterly results (Q1 FY27)

In its latest reported quarter, Q1 FY27, Jfl Life's revenue was ₹11.1 Cr (-4.2% year on year, -82.4% on the previous quarter), and net profit ₹1.1 Cr (+48.5% year on year); the operating margin was 18.9%.

Q1 FY27 (₹ Cr)	Value	YoY vs Q1 FY26	QoQ
Revenue	₹11.1	-4.2%	-82.4%
Operating profit	₹2.1	+8.5%	-40.4%
Net profit	₹1.1	+48.5%	-32.9%
EPS (₹)	0.34	+209.1%	+36.0%
Operating margin	18.9%	—	—

Full quarterly financials → Results calendar →

JFLLIFE delivery percentage

NSE end-of-day data for Fri, 16 Oct 2026

On Fri, 16 Oct 2026, 50.0% of the JFLLIFE shares traded on NSE were taken to delivery, against the stock's own 20-session average of 96.0%. That is lower than usual for this stock. Turnover was only ₹4 lakh, so a handful of trades can move this figure. It closed at a price band (circuit) on 5 sessions in about the last 20.

50.0%Delivery, 16 Oct

96.0%Own 20-session average

1.8×Volume vs its average

₹10.85NSE close · +0.00%

Delivery in the last 5 sessions: 100.0% · 100.0% · 100.0% · 100.0% · 50.0%

Delivery across the market →Circuit stocks →

A description of what the exchange published, not a recommendation. Names such as "accumulation" or "long buildup" label a pattern in the numbers. How delivery is analysed

📢 Recent Corporate Announcements

JFL Life Sciences Submits Demat Certificate Under Reg 74(5) for Q2 Ended Sep 30, 2026

🟡 NEUTRAL ⭐ 1/10

ROUTINE 📅 02 Oct 2026, 07:28 PM

JFL Life Sciences Limited has submitted its quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. The certificate, issued by Registrar and Share Transfer Agent KFin Technologies Limited, covers the quarter from July 01, 2026, to September 30, 2026. It confirms that details of securities dematerialized and rematerialized during this period were reported to the relevant stock exchanges. This is a recurring administrative filing and involves no financial or operational impact.

Compliance certificate submitted under Regulation 74(5) for Q2 ended September 30, 2026
Issued by Registrar and Share Transfer Agent KFin Technologies Limited
Covers dematerialization/rematerialization activity between July 01, 2026, and September 30, 2026

💡 Track the upcoming quarterly financial results announcements for operational and financial performance updates; no action needed on this procedural filing.

JFL Life Sciences Approves 5-Year Re-Appointments for MD, WTD, and Independent Directors at 16th AGM

🟡 NEUTRAL ⭐ 3/10

MANAGEMENT 📅 26 Aug 2026, 11:12 PM

JFL Life Sciences Limited has announced the reappointment of its key leadership team and independent directors at its 16th Annual General Meeting. Managing Director Smiral Ashwinkumar Patel and Whole-time Director Tejal Smiral Patel have both been reappointed for 5-year terms from January 18, 2027, to January 17, 2032. Additionally, Non-Executive Independent Directors Sonu Lalitkumar Jain (Jan 18, 2027 - Jan 17, 2032) and Bhavna Basantbhai Shah (Feb 10, 2027 - Feb 9, 2032) were reappointed for second 5-year terms. The company reported TTM revenue of ₹131 Cr and TTM PAT of ₹7 Cr.

Re-appointment of MD Smiral Ashwinkumar Patel for a 5-year term from January 18, 2027, to January 17, 2032
Re-appointment of Whole-Time Director Tejal Smiral Patel for a 5-year term from January 18, 2027, to January 17, 2032
Re-appointment of Independent Director Sonu Lalitkumar Jain for a second 5-year term ending January 17, 2032
Re-appointment of Independent Director Bhavna Basantbhai Shah for a second 5-year term from February 10, 2027, to February 9, 2032

💡 Track operational execution, upcoming quarterly earnings, and working capital management (inventory and receivables standing at ₹69.79 Cr).

JFL Life Sciences Approves Re-Appointment of MD, WTD, and 2 Independent Directors for 5-Yr Terms

🟡 NEUTRAL ⭐ 3/10

MANAGEMENT 📅 26 Aug 2026, 11:09 PM

JFL Life Sciences Limited has announced the re-appointment of its core leadership team and independent directors at its 16th Annual General Meeting. Mr. Smiral Ashwinkumar Patel (Managing Director) and Mrs. Tejal Smiral Patel (Whole-time Director) have been re-appointed for a five-year term from January 18, 2027 to January 17, 2032. Additionally, Ms. Sonu Lalitkumar Jain and Ms. Bhavna Basantbhai Shah were re-appointed as Non-Executive Independent Directors for five-year terms starting January 18, 2027 and February 10, 2027, respectively. The moves ensure continuity in governance and executive leadership for the Rs 59 Cr market cap company.

Re-appointment of Smiral Ashwinkumar Patel as Managing Director for 5 years (Jan 18, 2027 to Jan 17, 2032)
Re-appointment of Tejal Smiral Patel as Whole-Time Director for 5 years (Jan 18, 2027 to Jan 17, 2032)
Sonu Lalitkumar Jain re-appointed as Independent Director for a 2nd term of 5 years (Jan 18, 2027 to Jan 17, 2032)
Bhavna Basantbhai Shah re-appointed as Independent Director for a 2nd term of 5 years (Feb 10, 2027 to Feb 09, 2032)

💡 Track regular quarterly earnings execution and working capital management, particularly high inventory and receivables levels, as board composition remains stable.

JFL Life Sciences Re-Appoints MD, WTD & 2 Independent Directors for 5-Year Terms

🟡 NEUTRAL ⭐ 3/10

MANAGEMENT 📅 26 Aug 2026, 11:06 PM

JFL Life Sciences Limited announced shareholder approval at its 16th AGM for the re-appointment of core leadership. Smiral Ashwinkumar Patel has been re-appointed as Managing Director for 5 years from January 18, 2027 to January 17, 2032. Additionally, Tejal Smiral Patel (Whole-time Director) and Sonu Lalitkumar Jain (Independent Director) were re-appointed for 5-year terms effective January 18, 2027, alongside Bhavna Basantbhai Shah (Independent Director) effective February 10, 2027. These re-appointments ensure leadership and board continuity for the Rs 59 Cr market cap formulations company.

Smiral Ashwinkumar Patel re-appointed as Managing Director for 5 years (18th January, 2027 to 17th January, 2032)
Tejal Smiral Patel re-appointed as Whole-Time Director for 5 years (18th January, 2027 to 17th January, 2032)
Sonu Lalitkumar Jain re-appointed as Non-Executive Independent Director for a 2nd term of 5 years (18th January, 2027 to 17th January, 2032)
Bhavna Basantbhai Shah re-appointed as Non-Executive Independent Director for a 2nd term of 5 years (10th February, 2027 to 9th February, 2032)

💡 Track operational execution, working capital cycle management (inventory and receivables), and upcoming quarterly financial performance.

JFLLIFE Approves 5-Year Re-Appointment of MD Smiral Patel and Directors at 16th AGM

🟡 NEUTRAL ⭐ 3/10

MANAGEMENT 📅 26 Aug 2026, 10:58 PM

Jfl Life Sciences Limited has approved the re-appointment of Mr. Smiral Ashwinkumar Patel as Managing Director for a 5-year term starting January 18, 2027, through January 17, 2032, at its 16th AGM. Shareholders also approved 5-year reappointment terms for Whole-Time Director Mrs. Tejal Smiral Patel and Independent Director Ms. Sonu Lalitkumar Jain (both effective January 18, 2027), along with Independent Director Ms. Bhavna Basantbhai Shah (effective February 10, 2027). The approvals ensure leadership stability for the micro-cap formulations company (market cap Rs 59 Cr, FY26 revenue Rs 131.39 Cr).

Mr. Smiral Ashwinkumar Patel re-appointed as Managing Director for 5 years from January 18, 2027 to January 17, 2032
Mrs. Tejal Smiral Patel re-appointed as Whole-Time Director for 5 years from January 18, 2027 to January 17, 2032
Ms. Sonu Lalitkumar Jain re-appointed as Independent Director for a 2nd term of 5 years (Jan 18, 2027 to Jan 17, 2032)
Ms. Bhavna Basantbhai Shah re-appointed as Independent Director for a 2nd term of 5 years (Feb 10, 2027 to Feb 9, 2032)

💡 Monitor ongoing quarterly financial execution and working capital management, particularly inventory and trade receivable cash collection cycles.

JFLLIFE Approves Re-Appointment of MD Smiral Patel & 3 Directors for 5-Year Terms

🟡 NEUTRAL ⭐ 3/10

MANAGEMENT 📅 26 Aug 2026, 10:51 PM

JFL Life Sciences Limited announced shareholder approval at its 16th Annual General Meeting for the re-appointment of key leadership for five-year terms. Managing Director Mr. Smiral Ashwinkumar Patel and Whole-time Director Mrs. Tejal Smiral Patel were re-appointed for a 5-year period starting January 18, 2027 to January 17, 2032. Additionally, Non-Executive Independent Directors Ms. Sonu Lalitkumar Jain and Ms. Bhavna Basantbhai Shah were re-appointed for second 5-year terms commencing in January and February 2027, respectively. The decisions ensure continuity in leadership and board oversight for the ₹59 Cr market cap company.

Re-appointment of Mr. Smiral Ashwinkumar Patel as Managing Director for 5 years (January 18, 2027 to January 17, 2032)
Re-appointment of Mrs. Tejal Smiral Patel as Whole-Time Director for 5 years (January 18, 2027 to January 17, 2032)
Re-appointment of Ms. Sonu Lalitkumar Jain as Independent Director for a second 5-year term ending January 17, 2032
Re-appointment of Ms. Bhavna Basantbhai Shah as Independent Director for a second 5-year term ending February 9, 2032

💡 Track subsequent quarterly financial performances and working capital management, particularly high receivables and inventory levels.

JFL Life Sciences Submits Voting Results & Scrutinizer Report for 16th AGM

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 26 Aug 2026, 10:37 PM

JFL Life Sciences Limited has submitted the voting results and Scrutinizer's Report for its 16th Annual General Meeting (AGM) held on August 25, 2026. The remote e-voting window was open from August 22, 2026, to August 24, 2026, for shareholders holding equity as of the August 19, 2026 cut-off date. This filing represents a routine post-AGM statutory compliance requirement under Regulation 44(3) of SEBI LODR Regulations.

16th Annual General Meeting successfully conducted on August 25, 2026, via VC/OAVM
E-voting window concluded on August 24, 2026 at 5:00 p.m.
Shareholder eligibility cut-off date fixed at August 19, 2026
Submission made under Regulation 44(3) of SEBI LODR Regulations

💡 Track the company's upcoming quarterly financial results and working capital cycles, particularly receivable and inventory management.

JFL Life Sciences Concludes 16th AGM; 6 Resolutions Put to Vote

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 25 Aug 2026, 05:53 PM

JFL Life Sciences Limited conducted its 16th Annual General Meeting on August 25, 2026, via Video Conferencing with 16 members present. The meeting considered Item Nos. 1 through 6 as set out in the AGM notice dated July 31, 2026. The company noted that the Statutory and Secretarial Auditors' Reports for FY26 contained no qualifications or adverse remarks. Consolidated voting results and the scrutinizer's report will be declared within the prescribed regulatory timelines.

16th AGM successfully held on August 25, 2026, from 2:00 PM to 2:17 PM IST
Total of 16 members attended the meeting through Video Conferencing
E-voting was conducted for Item Nos. 1 to 6 with the cut-off date set as August 19, 2026
Statutory Auditors' and Secretarial Auditors' reports for FY26 had zero qualifications or adverse remarks

💡 Track the formal submission of consolidated voting results and Scrutinizer's report on the NSE to confirm adoption of all AGM resolutions.

JFL Life Sciences Q1 Net Profit Grows 49% YoY to ₹1.11 Cr; Revenue Dips 4% to ₹11.10 Cr

🟡 NEUTRAL ⭐ 5/10

EARNINGS 📅 10 Aug 2026, 05:39 PM

JFL Life Sciences reported a 49.3% YoY increase in Net Profit to ₹1.11 Cr for Q1 FY27, up from ₹0.75 Cr in Q1 FY26. This profit growth was achieved despite a 4.2% decline in Revenue from Operations, which stood at ₹11.10 Cr. The results highlight significant sequential volatility, as revenue dropped 82.4% from the outlier ₹63.05 Cr reported in Q4 FY26. The company managed to reduce total expenses by 5.2% YoY, which supported the bottom-line growth.

Net Profit increased to ₹1.11 Cr from ₹0.75 Cr in the same quarter last year, a growth of 49.3%.
Revenue from Operations stood at ₹11.10 Cr, a slight decline from ₹11.59 Cr in Q1 FY26.
Total Expenses decreased to ₹9.63 Cr from ₹10.16 Cr YoY, primarily due to lower material costs.
Earnings Per Share (EPS) improved to ₹0.34 from ₹0.23 in the year-ago period.
Profit Before Tax (PBT) margin improved slightly to 13.4% compared to 12.3% in Q1 FY26.

💡 Investors should monitor the company's ability to stabilize its quarterly revenue, as the sharp drop from Q4 FY26 suggests highly lumpy order execution or seasonal factors.

JFL Life Sciences Schedules 16th AGM for Aug 25; Proposes 5-Year MD Re-appointment

🟡 NEUTRAL ⭐ 4/10

BOARD_MEETING 📅 31 Jul 2026, 04:34 PM

JFL Life Sciences has scheduled its 16th Annual General Meeting (AGM) for August 25, 2026, to adopt FY26 financial statements and vote on key leadership roles. The company reported a 60% increase in FY26 revenue to ₹131.39 cr, with net profit rising to ₹6.4 cr. A major agenda item is the re-appointment of Managing Director Smiral Ashwinkumar Patel for a five-year term starting January 2027. Investors should note the Debt-Equity ratio increased by 76% to 0.47 during the year due to new business and vehicle loans.

FY26 Revenue grew 60.1% year-on-year to ₹131.39 cr from ₹82.03 cr in FY25
Net Profit for FY26 increased to ₹6.4 cr, resulting in a Return on Equity (ROE) of 15%
Debt-Equity ratio rose 76% to 0.47 following the acquisition of new business loan facilities
Proposed 5-year re-appointment of MD Smiral Ashwinkumar Patel and WTD Tejal Smiral Patel until January 2032
Debt Service Coverage Ratio (DSCR) improved significantly to 13.02 from 1.05 in the previous year

💡 Monitor the voting results of the AGM on August 25, 2026, to confirm leadership continuity and review the full Integrated Annual Report for details on the utilization of new debt facilities.

View All JFLLIFE Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Not disclosed in available documents. However, Profit Before Tax (PBT) for H1 FY26 stood at INR 3.65 Cr, which on an annualized basis (INR 7.30 Cr) represents a 19.05% increase over the FY25 PBT of INR 6.13 Cr.

Geographic Revenue Split

Not disclosed in available documents. Operations are concentrated in Ahmedabad, Gujarat, with manufacturing units at Unit-I (Ahmedabad) and Unit-II (Bavla).

Profitability Margins

Operating profit before working capital changes for H1 FY26 was INR 4.86 Cr. PBT margin trends show an upward trajectory with H1 FY26 PBT at INR 3.65 Cr compared to the full year FY25 of INR 6.13 Cr, indicating improved operational efficiency in the first half of the year.

EBITDA Margin

Not explicitly disclosed as a percentage. Operating profit before working capital changes was INR 4.86 Cr for H1 FY26. Finance costs stood at INR 0.68 Cr (14% of operating profit) and Depreciation at INR 0.53 Cr (11% of operating profit).

Capital Expenditure

Additions to property, plant, and equipment for H1 FY26 were INR 0.096 Cr. Total Non-Current Assets as of September 30, 2025, were INR 11.97 Cr, a slight decrease from INR 12.41 Cr in March 2025 due to depreciation.

Credit Rating & Borrowing

Total borrowings as of September 30, 2025, were INR 11.20 Cr, consisting of INR 10.93 Cr in short-term current borrowings and INR 0.27 Cr in long-term borrowings. Finance costs for H1 FY26 were INR 68.74 Lakhs.

⚙️ Operational Drivers

Raw Materials

Not disclosed in available documents. The company operates in the life sciences/pharmaceutical sector, implying the use of Active Pharmaceutical Ingredients (APIs) and excipients.

Capacity Expansion

The company operates two manufacturing facilities: Unit-I at Ahmedabad and Unit-II at G.I.D.C. Kerala, Bavla, Ahmedabad. Specific MTPA or unit capacity figures were not disclosed.

Raw Material Costs

Not disclosed in available documents. However, inventories increased by 43% from INR 23.24 Cr in March 2025 to INR 33.23 Cr in September 2025, suggesting significant procurement activity.

📈 Strategic Growth

Expected Growth Rate

19%

Growth Strategy

The company is focusing on scaling its pharmaceutical manufacturing operations through its two units in Gujarat. The 43% increase in inventory (to INR 33.23 Cr) and 4.6% increase in trade receivables (to INR 36.55 Cr) suggest an aggressive push for market share and higher sales volumes in the upcoming quarters.

Products & Services

Pharmaceutical formulations and life sciences products manufactured at Unit-I and Unit-II.

Brand Portfolio

JFL Life Sciences.

🌍 External Factors

Industry Trends

The pharmaceutical industry is shifting toward higher compliance standards (Indian Accounting Standards/Ind AS) and more robust internal financial controls. JFLLIFE is positioning itself by maintaining unmodified audit opinions and complying with SEBI LODR regulations.

Competitive Moat

The company's moat is based on its established manufacturing infrastructure in Gujarat (Unit-I and Unit-II) and its compliance with corporate governance standards. However, high competition in the generic formulation space remains a challenge.

Macro Economic Sensitivity

The company is sensitive to healthcare spending and pharmaceutical regulatory changes in India, particularly in Gujarat where its units are located.

⚖️ Regulatory & Governance

Industry Regulations

The company complies with the Companies Act, 2013, and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It maintains a code of conduct for senior management and independent directors.

Taxation Policy Impact

The company paid INR 0.08 Lakhs in income tax during H1 FY26, compared to INR 102.39 Lakhs in FY25. Deferred tax liabilities stood at INR 31.61 Lakhs as of September 2025.

Legal Contingencies

The company reported no pending litigation as of March 31, 2025. There were no material foreseeable losses on long-term contracts or derivative contracts.